Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Cellular and Acellular Matrix-like Products (CAMP) for the Dermatologist

Description

In this presentation, Dr. Higher discusses Cellular and Acellular Matrix-like Products (CAMPs) specifically for dermatology. CAMPs are classified as biological, synthetic, or hybrid skin substitutes designed to encapsulate skin wounds temporarily or permanently, mimicking normal skin's structure and function. The classification by the Centers for Medicare & Medicaid Services (CMS) and the FDA includes cellular and acellular products. The talk highlights about 9 cellular products and around 60 acellular products, primarily used for chronic and acute wounds. Key examples include Apligraf and Dermagraft, with evidence supporting their efficacy in treating diabetic ulcers and venous leg ulcers demonstrating accelerated healing compared to standard treatments. The discussion also introduces various acellular matrices such as Integra and Oasis, noting their diverse applications in wound care, including surgical and traumatic wounds. Dr. Higher emphasizes the importance of managing underlying wounds and optimizing conditions before applying these products, as well as monitoring for complications. He concludes by underscoring CAMPs' advantages, such as easy application and no donor site morbidity, showcasing that non-wound care experts can effectively integrate them into managing various dermatological conditions.

View more

Conclusions

  • Skin substitutes are FDA-approved or cleared for various dermatologic conditions.
  • Skin substitutes can enhance healing in both acute and chronic ulcerations.
  • Non-wound expert dermatologists can effectively use skin substitutes in managing common skin disorders with ulcerations.
  • Skin substitutes provide easy application and possess a favorable safety profile without donor site morbidity.
  • Davison-Kotler E, Sharma V, Kang NV, García-Gareta E. A Universal Classification System of Skin Substitutes Inspired by Factorial Design. Tissue Eng Part B Rev. 2018;24(4):279-88.
  • Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134(3):293-300.
  • Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-5.
  • Eaglstein WH, Alvarez OM, Auletta M, Leffel D, Rogers GS, Zitelli JA, et al. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 1999;25(3):195-201.
  • Falabella AF, Valencia IC, Eaglstein WH, Schachner LA. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol. 2000;136(10):1225-30.
  • Marston WA, Hanft J, Norwood P, Pollak R; Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003 Jun;26(6):1701-5.
  • Bianchi C, Cazzell S, Vayser D, Reyzelman AM, Dosluoglu H, Tovmassian G. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix(R)) allograft for the treatment of venous leg ulcers. International wound journal. 2018;15(1):114-22.
  • Duchini G, Itin P, Arnold A. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents. Adv Skin Wound Care. 2011;24(5):217-20.